Literature DB >> 7506467

Interaction between tachykinins and CGRP in human skin.

J Wallengren1, Z Y Wang.   

Abstract

Substance P (SP), neurokinin A (NKA) and calcitonin gene-related peptide (CGRP) coexist in nerve fibres in the skin. CGRP causes erythema upon intracutaneous injection. The erythema is independent of axon reflexes and release of mast cell histamine. SP is known to produce a flare reaction that is dependent on axon reflexes and release of mast cell histamine. The flare reaction to NKA is known to depend predominantly on axon reflexes. The purpose of the present study was to investigate possible cooperation between SP and CGRP. SP was found to shorten the duration of the reddening induced by CGRP, injected concomitantly. NKA did not shorten the duration of the CGRP response. Local elimination of mast cells in the skin by treatment with compound 48/80 had the effect that SP lost its ability to shorten CGRP-evoked erythema. These observations support the suggestion that an SP-evoked release of proteolytic enzymes from mast cells could lead to accelerated degradation of CGRP.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7506467     DOI: 10.2340/0001555573259261

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  4 in total

1.  Skin blood flow responses to the iontophoresis of acetylcholine and sodium nitroprusside in man: possible mechanisms.

Authors:  S J Morris; A C Shore
Journal:  J Physiol       Date:  1996-10-15       Impact factor: 5.182

2.  Altered thermal hyperaemia in human skin by prior desensitization of neurokinin-1 receptors.

Authors:  Brett J Wong; Christopher T Minson
Journal:  Exp Physiol       Date:  2011-04-08       Impact factor: 2.969

3.  Nitric oxide and noradrenaline contribute to the temperature threshold of the axon reflex response to gradual local heating in human skin.

Authors:  Belinda L Houghton; Jessica R Meendering; Brett J Wong; Christopher T Minson
Journal:  J Physiol       Date:  2006-05-01       Impact factor: 5.182

Review 4.  Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC.

Authors:  Michael J Grant; Roy S Herbst; Sarah B Goldberg
Journal:  Nat Rev Clin Oncol       Date:  2021-06-24       Impact factor: 66.675

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.